Siemens Healthineers AG (OTCMKTS:SMMNY) Given Consensus Recommendation of “Buy” by Analysts

Siemens Healthineers AG (OTCMKTS:SMMNY) has earned an average rating of “Buy” from the seven research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and three have issued a strong buy rating on the company.

SMMNY has been the subject of a number of research reports. Zacks Research downgraded Siemens Healthineers from a “hold” rating to a “strong sell” rating in a research report on Friday, December 12th. Deutsche Bank Aktiengesellschaft lowered Siemens Healthineers from a “buy” rating to a “hold” rating in a research note on Thursday, December 4th. Finally, Royal Bank Of Canada started coverage on shares of Siemens Healthineers in a research note on Wednesday, December 17th. They set a “moderate buy” rating on the stock.

Siemens Healthineers Stock Performance

OTCMKTS:SMMNY opened at $27.04 on Friday. The firm’s 50-day moving average is $25.58 and its 200-day moving average is $26.86. Siemens Healthineers has a 52-week low of $23.28 and a 52-week high of $30.19.

Siemens Healthineers Company Profile

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.